Bristol Property Plant and Equipment Net vs Accounts Payable Analysis

BMY Stock

USD 47.84 0.42 0.87%

Bristol Myers financial indicator trend analysis is way more than just evaluating Bristol Myers Squibb prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bristol Myers Squibb is a good investment. Please check the relationship between Bristol Myers Property Plant And Equipment Net and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

Property Plant And Equipment Net vs Accounts Payable

Property Plant and Equipment Net vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bristol Myers Squibb Property Plant and Equipment Net account and Accounts Payable. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Bristol Myers' Property Plant and Equipment Net and Accounts Payable is 0.85. Overlapping area represents the amount of variation of Property Plant and Equipment Net that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Bristol Myers Squibb, assuming nothing else is changed. The correlation between historical values of Bristol Myers' Property Plant and Equipment Net and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant and Equipment Net of Bristol Myers Squibb are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Property Plant and Equipment Net i.e., Bristol Myers' Property Plant and Equipment Net and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.85

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Accounts Payable

An accounting item on the balance sheet that represents Bristol Myers obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Bristol Myers Squibb are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

At this time, Bristol Myers' Selling General Administrative is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 12.22 in 2024, whereas Discontinued Operations is likely to drop slightly above 6 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	36.4B	36.0B	34.3B	36.0B
Total Revenue	46.4B	46.2B	45.0B	47.3B

Gross Profit Total Revenue

Bristol Myers fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock Total Equity
Total Assets		0.98	0.81	0.93	0.89	0.78	0.98	-0.07	0.9	0.99	0.52	0.83	0.76	0.97	0.45	0.99	0.82	-0.16	0.88	0.99	0.7	0.94	0.85	0.96	0.6	0.88
Short Long Term Debt Total	0.98		0.78	0.92	0.84	0.79	1.0	-0.16	0.94	0.97	0.38	0.88	0.82	0.98	0.52	0.99	0.76	-0.24	0.89	0.99	0.76	0.95	0.89	0.95	0.57	0.91
Other Current Liab	0.81	0.78		0.95	0.55	0.69	0.81	-0.1	0.63	0.77	0.64	0.55	0.77	0.81	0.39	0.76	0.52	0.1	0.6	0.83	0.77	0.87	0.67	0.65	0.62	0.73
Total Current Liabilities	0.93	0.92	0.95		0.7	0.8	0.93	-0.07	0.81	0.89	0.52	0.75	0.88	0.95	0.41	0.9	0.66	-0.04	0.73	0.94	0.87	0.97	0.84	0.8	0.66	0.85
Total Stockholder Equity	0.89	0.84	0.55	0.7		0.75	0.84	0.13	0.79	0.91	0.41	0.73	0.5	0.82	0.44	0.88	0.9	-0.14	0.82	0.85	0.43	0.76	0.73	0.93	0.62	0.81
Property Plant And Equipment Net	0.78	0.79	0.69	0.8	0.75		0.79	0.28	0.73	0.76	0.19	0.7	0.77	0.84	0.41	0.78	0.64	-0.13	0.53	0.8	0.75	0.79	0.78	0.7	0.85	0.85
Net Debt	0.98	1.0	0.81	0.93	0.84	0.79		-0.17	0.9	0.98	0.42	0.83	0.82	0.98	0.52	0.99	0.77	-0.21	0.89	0.99	0.76	0.93	0.89	0.95	0.56	0.91
Retained Earnings	-0.07	-0.16	-0.1	-0.07	0.13	0.28	-0.17		-0.12	-0.07	-0.11	-0.07	-0.11	-0.03	-0.62	-0.12	0.17	0.35	-0.45	-0.11	-0.06	-0.05	-0.16	-0.13	0.44	-0.14
Cash	0.9	0.94	0.63	0.81	0.79	0.73	0.9	-0.12		0.87	0.21	0.98	0.78	0.9	0.48	0.92	0.66	-0.32	0.83	0.91	0.69	0.91	0.85	0.87	0.57	0.84
Non Current Assets Total	0.99	0.97	0.77	0.89	0.91	0.76	0.98	-0.07	0.87		0.53	0.8	0.71	0.95	0.46	0.99	0.84	-0.19	0.89	0.98	0.65	0.91	0.83	0.98	0.57	0.86
Non Currrent Assets Other	0.52	0.38	0.64	0.52	0.41	0.19	0.42	-0.11	0.21	0.53		0.12	0.16	0.38	0.18	0.45	0.49	0.12	0.44	0.48	0.18	0.45	0.18	0.45	0.21	0.35
Cash And Short Term Investments	0.83	0.88	0.55	0.75	0.73	0.7	0.83	-0.07	0.98	0.8	0.12		0.76	0.84	0.41	0.85	0.6	-0.37	0.74	0.84	0.67	0.87	0.8	0.8	0.58	0.78
Net Receivables	0.76	0.82	0.77	0.88	0.5	0.77	0.82	-0.11	0.78	0.71	0.16	0.76		0.88	0.35	0.76	0.48	-0.29	0.58	0.8	0.97	0.86	0.87	0.62	0.53	0.8
Good Will	0.97	0.98	0.81	0.95	0.82	0.84	0.98	-0.03	0.9	0.95	0.38	0.84	0.88		0.4	0.97	0.78	-0.19	0.81	0.98	0.83	0.95	0.9	0.9	0.63	0.89
Common Stock Shares Outstanding	0.45	0.52	0.39	0.41	0.44	0.41	0.52	-0.62	0.48	0.46	0.18	0.41	0.35	0.4		0.5	0.2	-0.34	0.69	0.48	0.29	0.4	0.52	0.5	0.27	0.64
Non Current Liabilities Total	0.99	0.99	0.76	0.9	0.88	0.78	0.99	-0.12	0.92	0.99	0.45	0.85	0.76	0.97	0.5		0.8	-0.22	0.9	0.99	0.69	0.93	0.86	0.97	0.58	0.88
Inventory	0.82	0.76	0.52	0.66	0.9	0.64	0.77	0.17	0.66	0.84	0.49	0.6	0.48	0.78	0.2	0.8		-0.07	0.72	0.78	0.45	0.69	0.65	0.86	0.52	0.75
Other Current Assets	-0.16	-0.24	0.1	-0.04	-0.14	-0.13	-0.21	0.35	-0.32	-0.19	0.12	-0.37	-0.29	-0.19	-0.34	-0.22	-0.07		-0.33	-0.18	-0.19	-0.07	-0.32	-0.24	0.15	-0.26
Other Stockholder Equity	0.88	0.89	0.6	0.73	0.82	0.53	0.89	-0.45	0.83	0.89	0.44	0.74	0.58	0.81	0.69	0.9	0.72	-0.33		0.87	0.49	0.77	0.78	0.94	0.3	0.81
Total Liab	0.99	0.99	0.83	0.94	0.85	0.8	0.99	-0.11	0.91	0.98	0.48	0.84	0.8	0.98	0.48	0.99	0.78	-0.18	0.87		0.75	0.96	0.87	0.95	0.61	0.89
Property Plant And Equipment Gross	0.7	0.76	0.77	0.87	0.43	0.75	0.76	-0.06	0.69	0.65	0.18	0.67	0.97	0.83	0.29	0.69	0.45	-0.19	0.49	0.75		0.82	0.83	0.55	0.56	0.75
Total Current Assets	0.94	0.95	0.87	0.97	0.76	0.79	0.93	-0.05	0.91	0.91	0.45	0.87	0.86	0.95	0.4	0.93	0.69	-0.07	0.77	0.96	0.82		0.85	0.84	0.68	0.86
Short Term Debt	0.85	0.89	0.67	0.84	0.73	0.78	0.89	-0.16	0.85	0.83	0.18	0.8	0.87	0.9	0.52	0.86	0.65	-0.32	0.78	0.87	0.83	0.85		0.82	0.53	0.84
Intangible Assets	0.96	0.95	0.65	0.8	0.93	0.7	0.95	-0.13	0.87	0.98	0.45	0.8	0.62	0.9	0.5	0.97	0.86	-0.24	0.94	0.95	0.55	0.84	0.82		0.5	0.83
Accounts Payable	0.6	0.57	0.62	0.66	0.62	0.85	0.56	0.44	0.57	0.57	0.21	0.58	0.53	0.63	0.27	0.58	0.52	0.15	0.3	0.61	0.56	0.68	0.53	0.5		0.64
Common Stock Total Equity	0.88	0.91	0.73	0.85	0.81	0.85	0.91	-0.14	0.84	0.86	0.35	0.78	0.8	0.89	0.64	0.88	0.75	-0.26	0.81	0.89	0.75	0.86	0.84	0.83	0.64

Click cells to compare fundamentals

Bristol Myers Account Relationship Matchups

Bristol Myers fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	129.9B	118.5B	109.3B	96.8B	95.2B	99.9B
Short Long Term Debt Total	47.5B	51.7B	45.6B	40.7B	41.5B	43.5B
Other Current Liab	7.9B	10.2B	10.1B	13.1B	11.5B	12.1B
Total Current Liabilities	18.3B	19.1B	21.9B	21.9B	22.3B	23.4B
Total Stockholder Equity	51.6B	37.8B	35.9B	31.1B	29.4B	15.0B
Property Plant And Equipment Net	6.3B	6.7B	7.0B	7.5B	8.0B	5.2B
Net Debt	35.2B	37.1B	31.6B	31.6B	30B	31.5B
Retained Earnings	34.5B	21.3B	23.8B	25.5B	28.8B	22.0B
Cash	12.3B	14.5B	14.0B	9.1B	11.5B	12.0B
Non Current Assets Total	100.6B	88.3B	76.1B	69.5B	63.4B	66.6B
Non Currrent Assets Other	6.6B	2.1B	1.7B	1.0B	1.9B	2.0B
Cash And Short Term Investments	12.3B	14.5B	14.0B	9.1B	12.3B	12.9B
Net Receivables	7.7B	8.5B	12.5B	13.9B	15.3B	16.0B
Good Will	22.5B	20.5B	20.5B	21.1B	21.2B	22.2B
Common Stock Shares Outstanding	1.7B	2.3B	2.2B	2.1B	2.1B	1.6B
Liabilities And Stockholders Equity	129.9B	118.5B	109.3B	96.8B	95.2B	99.9B
Non Current Liabilities Total	59.9B	61.5B	51.4B	43.8B	43.4B	45.6B
Inventory	4.3B	2.1B	2.1B	2.3B	2.7B	1.9B
Other Current Assets	2.0B	1.4B	1.3B	1.6B	1.5B	1.8B
Other Stockholder Equity	18.4B	18.1B	13.1B	6.5B	1.9B	2.0B
Total Liab	78.2B	80.6B	73.3B	65.7B	65.7B	69.0B
Property Plant And Equipment Gross	6.3B	5.9B	11.0B	11.6B	12.8B	13.5B
Total Current Assets	29.4B	30.2B	33.3B	27.3B	31.8B	33.4B
Accumulated Other Comprehensive Income	(1.5B)	(1.8B)	(1.3B)	(1.3B)	(1.5B)	(1.6B)
Short Term Debt	3.5B	2.5B	5.1B	4.4B	3.3B	3.4B
Intangible Assets	64.0B	53.2B	42.8B	36.4B	27.5B	28.9B
Accounts Payable	2.4B	2.7B	2.9B	3.0B	3.3B	1.9B
Short Term Investments	3.0B	1.3B	3.2B	130M	816M	775.2M
Other Liab	15.9B	12.3B	11.0B	7.4B	8.5B	4.9B
Other Assets	4.8B	7.3B	3.3B	2.9B	3.3B	3.3B
Long Term Debt	43.4B	48.3B	39.6B	35.1B	36.7B	38.5B
Treasury Stock	(19.6B)	(25.4B)	(26.2B)	(31.3B)	(28.1B)	(26.7B)
Property Plant Equipment	6.3B	5.9B	6.0B	6.3B	7.2B	5.8B
Current Deferred Revenue	4.5B	3.6B	3.7B	1.3B	4.2B	4.4B
Net Tangible Assets	(34.9B)	(36.0B)	(28.2B)	(25.9B)	(23.4B)	(22.2B)
Noncontrolling Interest In Consolidated Entity	96M	100M	60M	57M	65.6M	75.7M
Retained Earnings Total Equity	34.5B	21.3B	23.8B	25.5B	23.0B	24.5B

Bristol Myers Investors Sentiment

The influence of Bristol Myers' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bristol. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Bristol Myers' public news can be used to forecast risks associated with an investment in Bristol. The trend in average sentiment can be used to explain how an investor holding Bristol can time the market purely based on public headlines and social activities around Bristol Myers Squibb. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Bristol Myers' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bristol Myers' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Bristol Myers' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Bristol Myers.

Bristol Myers Implied Volatility

45.59

Bristol Myers' implied volatility exposes the market's sentiment of Bristol Myers Squibb stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Bristol Myers' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Bristol Myers stock will not fluctuate a lot when Bristol Myers' options are near their expiration.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bristol Myers in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bristol Myers' short interest history, or implied volatility extrapolated from Bristol Myers options trading.

Pair Trading with Bristol Myers

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bristol Stock

0.77

Agilent Technologies Financial Report 28th of May 2024

Pair Corr

Moving against Bristol Stock

0.55	BNR	Burning Rock BiotechLtd Financial Report 4th of June 2024	Pair Corr
0.46	VALN	Valneva SE ADR Financial Report 2nd of May 2024	Pair Corr

The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.

The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:

How To Invest In Bristol

Details

Is Bristol Stock a good investment?

Details

What is Bristol Myers' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.

	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	CEOs Directory Screen CEOs from public companies around the world
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Commodity Directory Find actively traded commodities issued by global exchanges
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets

Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.09)

Dividend Share

2.31

Earnings Share

3.86

Revenue Per Share

21.753

Quarterly Revenue Growth

0.006

The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bristol Property Plant and Equipment Net vs Accounts Payable Analysis

Property Plant And Equipment Net vs Accounts Payable

Property Plant and Equipment Net vs Accounts Payable Correlation Analysis

Correlation Coefficient

Property Plant And Equipment Net

Accounts Payable

Bristol Myers fundamental ratios Correlations

Bristol Myers Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bristol Myers fundamental ratios Accounts

Bristol Myers Investors Sentiment

Bristol Myers Implied Volatility

Pair Trading with Bristol Myers

Moving together with Bristol Stock

Moving against Bristol Stock

Complementary Tools for Bristol Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Debt	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total

Common Stock Shares Outstanding	- 0.62	Retained Earnings
Other Stockholder Equity	- 0.45	Retained Earnings
Other Current Assets	- 0.37	Cash And Short Term Investments
Other Current Assets	- 0.34	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.33	Other Current Assets
Short Term Debt	- 0.32	Other Current Assets